August 7, 2020
Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) was the top-seller in Japan in July with sales of 10 billion yen on an NHI price basis, barely outstripping its archrival Keytruda (pembrolizumab), according to a monthly snapshot report released by market research...read more